Immunovant Q1 2027 Earnings Call Transcript

The Motley Fool··US·Read original
2▲2 ▼1Impact / 5
Summary · why it matters

Immunovant reported a cash balance of $797.8 million as of June 30, 2026, which management stated provides a runway to the potential commercial launch of IMVT-1402 in Graves' disease. Research and development expenses were $142.6 million for the quarter, compared to $101.2 million in the prior year, primarily due to increased clinical trial activities for IMVT-1402 and contract manufacturing costs. The company reported a net loss of $153.2 million, or $0.75 per common share, for the three months ended June 30, 2026, and a non-GAAP net loss of $139.4 million excluding $13.8 million in non-cash stock-based compensation. Management expects topline data from the proof-of-concept trial in cutaneous lupus erythematosus in the second half of 2026, and topline data for the potentially registrational trials in Graves' disease and myasthenia gravis in calendar year 2027. Roivant, the parent company, received an upfront payment of $950 million from the Moderna settlement, with $770 million allocated to Genevant and the remainder to Arbutus, and reported a cash balance of just under $4 billion prior to the receipt of the Moderna settlement funds.

Impact on assets 4

Biotech & Genomic Medicine± Mixed · 4 stocks

Off-coverage companies 1

Genevant SciencesPrivate▲ Positive
Capitalrelevance

Allocated $770M from Moderna settlement

© 2026 MarketIVNews